Ukwelashwa Komdlavuza Wamaphaphu Okuyisisekelo 2026: Izinkombandlela Ezintsha Nemithi Yokwelapha Yakamuva 

Ukwelashwa komdlavuza wamaphaphu okuyisisekelo ngo-2026 kugxile ekwelashweni okunembayo, okuhlanganisa ukuhlolwa kwe-biomarker okuthuthukisiwe nokwelashwa kwesistimu okuhambisanayo. Njengembangela ehamba phambili yokufa komdlavuza emhlabeni jikelele, abaphathi manje bathembele esiteji se-AJCC 9th Edition kanye nemihlahlandlela ye-NCCN ebuyekeziwe. Izindinganiso zamanje zigcizelela ukuphrofayela yamangqamuzana kubashayeli abafana ne-EGFR, HER2, kanye ne-KRAS ukuze bakhethe ama-agent ahlosiwe afanele noma ama-immunotherapies ngaphambi kokucabangela ukwelashwa ngamakhemikhali okungokwesiko.

Ukuqonda Umdlavuza Oyinhloko Wamaphaphu kanye Namazinga Okuxilongwa Ka-2026

Umdlavuza wamaphaphu oyinhloko uvela ezicutshini zamaphaphu, ezihlukaniswa kakhulu zibe umdlavuza wamaphaphu ongewona omncane (NSCLC) kanye nomdlavuza wamaphaphu omncane (SCLC). I-NSCLC ithatha cishe u-85% wazo zonke izimo, okuhlanganisa i-adenocarcinoma kanye ne-squamous cell carcinoma subtypes. Ukuxilongwa okunembile kuyisisekelo sokusebenza ngempumelelo ukwelashwa komdlavuza wamaphaphu okuyinhloko, enquma ukuthi isiguli siyakufanelekela yini ukuhlinzwa okwelaphayo noma sidinga ukuphathwa kwesistimu.

Ngo-2026, izinqubo zokuxilonga ziye zavela ngokuphawulekayo ngokwamukelwa kwendawo yonke yohlelo lwesiteji lwe-AJCC 9th Edition TNM. Lesi sibuyekezo sinikeza idatha yokubikezela eyimbudumbudu eyengeziwe, okuvumela odokotela ukuba bahlukanise phakathi kokubandakanyeka kwe-nodal encane ngokunemba okukhulu. Uguquko luqinisekisa ukuthi izinqumo zokwelashwa zihambisana namazinga omhlaba, okwenza imiphumela yokusinda ibe ngcono ngezindlela zokunakekelwa komuntu siqu.

Iqhaza Elibalulekile Lokuhlolwa Kwe-Biomarker

Ukuhlolwa okuphelele kwe-biomarker sekuyimpoqo ngaphambi kokuqala ukwelashwa kwezifo ezithuthukile. Itemu leyenziwe yalingana “nokuhlola i-biomarker,” esikhundleni samagama amadala afana nokuhlolwa kwamangqamuzana noma ufuzo. Imihlahlandlela yesimanje incoma indlela embaxambili kusetshenziswa i-tissue biopsy ehambisana ne-plasma liquid biopsy ukuze kukhuliswe amazinga okutholwa.

• Abashayeli Ababalulekile: Ukuhlola kufanele kufake i-EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, kanye ne-ERBB2 (HER2).
• Okuqondisiwe Abasafufusa: Ama-NRG1 fusions manje ahlolwa ngokujwayelekile kusetshenziswa i-RNA-based Next Generation Sequencing (NGS).
• Izimpawu ze-Immunotherapy: Amazinga we-PD-L1 ahlala ebalulekile ekunqumeni ukufaneleka kwama-checkpoint inhibitors.

Uma imiphumela ye-biomarker isalindile, izivumelwano zamanje zeluleka ukubambezeleka kokuqaliswa kwe-immunotherapy ukuze kuvinjwe ukuqhubekela phambili okungase kube khona noma ukuncipha kokuphumelela kubantu abanomshayeli. Le ndlela yokuqapha igcizelela ukushintshela ekushayeleni idatha ukwelashwa komdlavuza wamaphaphu okuyinhloko amasu.

Izinkombandlela Zokwelashwa Ezibuyekeziwe Zomdlavuza Ongewona Omncane Wengqamuzana Wamaphaphu

Isimo sokuphathwa kwe-NSCLC sishintshile ngokukhishwa kwe-2026 NCCN Clinical Practice Guidelines. Lezi zibuyekezo zibonisa ukuqonda okujulile kwe-tumor biology kanye nokutholakala kwama-ejenti amanoveli okwelapha. Imihlahlandlela ibeka phambili izindlela zokwelapha ezihlosiwe ezigulini ezinokuguquguquka okunokwenzeka, ezigcina i-chemotherapy kanye ne-immunotherapy ngezimo ezithile noma isifo esingenalo umshayeli.

Umugqa Wokuqala Wokwelapha Wezinguquko Ezisebenzayo

Ezigulini eziphethe izinguquko ezithile zofuzo, i-tyrosine kinase inhibitors (TKIs) imele izinga legolide. Isibuyekezo esiyingqophamlando ekuqaleni kuka-2026 sihlanganisa isincomo se-zonugritinib sokwelashwa komugqa wokuqala we-metastatic NSCLC nge-ERBB2 (HER2) ukuguqulwa kwesizinda se-tyrosine kinase. Lokhu kugunyazwa kulandela idatha ephoqelelayo evela ocwaningweni lwe-Beamion LUNG-1, ebonisa izilinganiso zokuphendula eziphokophele kanye nokusinda okuhlala isikhathi eside ngaphandle kokuqhubekela phambili.

Ngaphambilini, umdlavuza wamaphaphu oguquguqukayo we-HER2 ubungenazo izinketho eziqondiwe ezisebenzayo, okuvame ukuphoqa ukuthembela kuma-antibody-drug conjugates ngemuva kokwehluleka kwe-chemotherapy. Ukufakwa kwe-TKI enamandla, engenakuhlehliswa kushintsha i-algorithm yokwelapha, inikeze inketho yomlomo ebekezelelwe kahle enenzuzo ebalulekile yomtholampilo. Lokhu kuyisibonelo sejubane elisheshayo lokuqamba izinto ezintsha ukwelashwa komdlavuza wamaphaphu okuyinhloko.

Okunye okuhlosiwe okumisiwe kuyaqhubeka nokubona ukucoliswa. Ngesifo esiguquliwe se-EGFR, ama-TKI esizukulwane sesithathu ahlala ewumgogodla, kuyilapho izinhlanganisela ezintsha zihlose ukunqoba izindlela zokumelana. Ngokufanayo, i-ALK inhibitors iye yavela ukuze inikeze ukungena kwesistimu yezinzwa emaphakathi, ibhekana nesayithi elivamile lokuphindeka.

I-Immunotherapy ne-Chemotherapy Inhlanganisela

Uma kungekho ukuguqulwa komshayeli, i-chemo-immunotherapy ihlala iyindinganiso yokunakekelwa kweziguli eziningi ezine-NSCLC ethuthukisiwe. Imihlahlandlela yango-2026 yenza ngcono ukukhethwa kwesiguli okusekelwe kusisho se-PD-L1 nama-subtypes e-histological. Ngokuphawulekayo, incazelo “yengozi enkulu” yokuphinda inwetshiwe ukuze ifake izici ezithile zamangqamuzana ngisho nasesigabeni sokuqala.

Amasu e-Neoadjuvant asezuze amandla, kusetshenziswa i-immunotherapy ehlanganiswe ne-platinum-doublet chemotherapy ngaphambi kokuhlinzwa. Izibuyekezo zakamuva zicacisa ukulungiswa kwesimiso, njengokushintsha i-paclitaxel ne-docetaxel kuzinhlanganisela ezithile ezisuselwe ku-cisplatin ukuze kuthuthukiswe ukubekezeleleka ngaphandle kokufaka engozini ukusebenza kahle. Le ndlela ye-perioperative ihlose ukwehlisa izimila nokuqeda ama-micrometastase kusenesikhathi.

Intuthuko Ekulawuleni Umdlavuza Wamaphaphu Amaseli Amancane

Umdlavuza wamaphaphu omncane (i-SCLC) usalokhu uyisifo esiyingozi esibonakala ngokukhula ngokushesha kanye ne-metastasis yokuqala. Ngenkathi belashwa ngokomlando ngemithi efanayo yokwelapha ngamakhemikhali, imihlahlandlela ka-2026 yethula izindlela eziguquguqukayo ezisuselwa kuphrofayili yamangqamuzana nezindlela ezicolisisiwe zemisebe. Lezi zinguquko zihlose ukuthuthukisa amazinga okusinda anesizotha ahlobene nesifo esisezingeni eliphezulu.

Iphrofayela ye-Molecular ku-SCLC

Ushintsho olubalulekile kuzinkombandlela zika-2026 luyisincomo esicacile sokuhlonza iphrofayili yamangqamuzana kumasethi amancane e-SCLC. Iziguli ezingabhemi, ezibhema kancane, noma lezo ezinokungaqiniseki kokuxilonga manje zihlolwa kabanzi ngofuzo. Lolu shintsho luvuma ukuthi isethi engaphansi yamacala e-SCLC ingase ibe nezinguquko ezingenzeka noma ilingise ezinye izimila ze-neuroendocrine.

• Inani labantu eliqondiwe: Abangabhemi noma labo ababhemayo ngaphansi kwamaphakethe ayi-10 ngonyaka.
• Usizo Lomtholampilo: Ukuhlonza okungase kuqondiswe ekuhlolweni komtholampilo noma izindlela zokwelapha eziqondiswe ngaphandle kwelebula.
• Ukuhlola kabusha: Ukuhlola okuyisibopho kwamangqamuzana lapho kuphindeka uma kungenziwanga ngaphambili.

Le ndlela yokwelapha enembayo iletha i-SCLC eduze kwamamodeli okwelapha omuntu siqu abonwa ku-NSCLC, enikeza ithemba ezigulini ezingaphenduli ezinhlotsheni ezijwayelekile ze-platinum-etoposide.

Ukuthuthukisa Ukwelashwa Kwemisebe

Imisebe ye-thoracic isalokhu iyingxenye ebalulekile yokwelashwa kwe-SCLC yesigaba esilinganiselwe. Imihlahlandlela yakamuva ivumela ngokuqinile I-Intensity-Modulated Radiation Therapy (IMRT) phezu kwemisebe ehambisanayo enezinhlangothi ezintathu (3D-CRT). Ubufakazi bubonisa ukuthi i-IMRT inciphisa kakhulu ubuthi ezicutshini ezizungezile ezinempilo kuyilapho igcina ukulawulwa kwesimila phakathi ne-chemoradiation efanayo.

Ngaphezu kwalokho, izinkomba zokuhlinzwa ziqinisiwe. Ukuhlinzwa manje kugcinelwe ngokuqinile esigabeni somtholampilo I-IIA isifo esiqinisekiswa yisiteji esihlaselayo se-mediastinal. Lokhu kuqinisekisa ukuthi iziguli kuphela ezinesifo sendawo ngempela ezikhishwa kabusha, kugwenywe izinqubo eziyize kulabo abanokuhileleka kwamanodal okulumba.

Izindlela Zokwelapha Ezisafufusa kanye Nezinhlelo Zokulethwa Kwenoveli

Ipayipi le ukwelashwa komdlavuza wamaphaphu okuyinhloko iyaqhubeka nokwanda ngokwenziwa kwezidakamizwa ezintsha nezindlela zokulethwa. Le ntuthuko ihlose ukuthuthukisa ukunethezeka kwesiguli, ukunciphisa ukusabela okuhlobene nokumnika, nokuthuthukisa i-pharmacokinetics yezidakamizwa. Ukwakhiwa kwe-subcutaneous kanye ne-novel radiopharmaceuticals kuhamba phambili kulokhu kuqubuka.

I-subcutaneous Biologics

Ukuthuthukiswa okuphawulekayo kwekhwalithi yokuphila kuvela ekugunyazweni kokwakheka okungaphansi kwesikhumba kwamasosha omzimba e-monoclonal. Ama-ejenti afana ne-amivantamab, ngaphambili ayesetshenziswa ngokufakwa emthanjeni omude, manje anikeza izinketho zomjovo ongaphansi kwe-hyaluronidase owenziwe lula. Lolu shintsho lunciphisa kakhulu isikhathi sesitulo ezigulini futhi lwehlise umthwalo ezikhungweni zokumnika.

Ngokufanayo, i-pembrolizumab ibone intuthuko kwezinye izindlela zokulethwa, okuhlanganisa ukwakhiwa komjovo wemisipha ezimweni ezithile. Lezi zindlela ezintsha zigcina ukusebenza kahle kokwelapha ngenkathi kulungiswa inqubo yokuphatha, okwenza ukwelashwa kwesondlo isikhathi eside kulawuleke kakhulu ezigulini ezinezifo ezingelapheki eziphambili.

Ukuphumelela Kwemithi Yenuzi

I-nuclear oncology ibone ingqophamlando ngokugunyazwa komjovo we-peptide we-technetium-99m we-pexipretide. Njengomenzeli wokuqala wokuthwebula we-SPECT womhlaba wonke oqondise i-integrin αvβ3, inika amandla ukubonwa okunembe kwe-tumor angiogenesis. Nakuba ngokuyinhloko ithuluzi lokuxilonga, ikhono layo lokuhlonza i-lymph node metastasis ezimweni zomdlavuza wamaphaphu asolisayo lilungisa ukunemba kwesiteji.

Isiteji esinembile sithinta ngokuqondile ukukhethwa kokwelashwa, kuqinisekisa ukuthi iziguli zithola okufanele kakhulu ukwelashwa komdlavuza wamaphaphu okuyinhloko umfutho. Ngokuhlukanisa phakathi kwezifo ezitholakala endaweni nesabalaliswa ngokuzwela okuphezulu, odokotela bangagwema ukwelashelwa ezigabeni zokuqala noma bakhulise ukwelashwa ngokushesha ezimeni ezithuthukile.

Ukuhlaziywa Okuqhathaniswayo Kwezindlela Zokwelapha

Ukukhetha ukwelashwa okufanele kudinga ukulinganisa ukusebenza kahle, ubuthi, kanye nezici eziqondene nesiguli. Ithebula elilandelayo liqhathanisa izindlela eziyinhloko ezisetshenziswe ngo-2026 zomdlavuza wamaphaphu othuthukile, ligqamisa izindima zabo ezihlukile ohlelweni lwendawo yokwelapha.

Lesi siqhathaniso sibonisa ukuthi ayikho indlela eyodwa efanela zonke. Ithrendi ngokusobala iqhubekela kumasu alandelanayo noma ahlangene asebenzisa amandla endlela ngayinye kuyilapho enciphisa ubuthakathaka bawo.

Izinyathelo Ezisebenzayo Zeziguli Nabanakekeli

Ukuzulazula ekuxilongweni komdlavuza wamaphaphu kungaba nzima. Ukuqonda ukuhamba komsebenzi wesimanje ukwelashwa komdlavuza wamaphaphu okuyinhloko inika amandla iziguli ukuthi zibambe iqhaza ekunakekeleni kwazo. Izinyathelo ezilandelayo ziveza uhambo olujwayelekile ukusuka ekuxilongweni kuya ekuqalisweni kokwelashwa endaweni yokunakekelwa kwezempilo ka-2026.

• Isinyathelo 1: Isiteji Esiphelele: Yenza i-PET/CT kanye ne-MRI yobuchopho ukuze unqume izinga lesifo. Qinisekisa ukuthi isiteji se-mediastinal esihlaselayo siyenziwa uma kucatshangelwa ukuhlinzwa.
• Isinyathelo sesi-2: Ukwenza iphrofayela ye-Biomarker: Cela ukuhlolwa okubanzi kwamangqamuzana okuhlanganisa i-DNA kanye ne-RNA-based NGS. Ungaqali i-immunotherapy kuze kube yilapho imiphumela isitholakala ngaphandle uma iphuthuma ngokomtholampilo.
• Isinyathelo sesi-3: Ukubuyekezwa Kwemikhakha Ehlukahlukene: Xoxa ngezimo ebhodini lesimila elihlanganisa odokotela abahlinzayo, izazi zezokwelapha, nodokotela be-radiation oncologists ukuze benze uhlelo lokuvumelana.
• Isinyathelo sesi-4: Ukukhethwa Kokwelashwa: Khetha ukwelashwa okusekelwe esimweni samangqamuzana. Beka kuqala ama-ejenti aqondiswe kubashayeli, alandelwe yinhlanganisela ye-chemo-immunotherapy.
• Isinyathelo sesi-5: Ukuhlanganiswa Kokunakekelwa Okusekelayo: Faka ukunakekelwa kwe-palliative kusenesikhathi ukuze ulawule izimpawu nemiphumela engemihle, uthuthukise ikhwalithi yokuphila iyonke.

Ukunamathela kule ndlela ehlelekile kuqinisekisa ukuthi iziguli zithola ukunakekelwa okuhambisana neziqondiso, okwandisa amathuba okuba nemiphumela emihle.

Izinselele kanye Neziqondiso Zesikhathi esizayo

Naphezu kwenqubekelaphambili emangalisayo, izinselele zisaqhubeka endaweni ye ukwelashwa komdlavuza wamaphaphu okuyinhloko. Ukumelana nemithi ehlosiwe kuyakhula nakanjani, okwenza kudingeke ukuthi kuthuthukiswe izithiyo zesizukulwane esilandelayo kanye namasu ahlangene. Ngaphezu kwalokho, ukufinyelela ekuxilongweni okuthuthukile kanye nemithi emisha kuhlala kungalingani ezifundeni ezihlukene zejografi nezomnotho.

Ukunqoba Izindlela Zokumelana

I-Tumor heterogeneity kanye nokumelana nokuguquguquka yizithiyo ezinkulu. Ucwaningo lugxile kakhulu ekuqondeni ukuvela kwamangqamuzana ezimila ngaphansi kwengcindezi yokwelapha. Amaqhinga afana nokudoswa kwezidakamizwa ngezikhathi ezithile, amaholide ezidakamizwa, nezinhlanganisela eziphusile ze-TKIs ne-immunotherapies ziyahlolwa ukuze kubambezeleke ukumelana.

Isibonelo, kumdlavuza wamaphaphu oguquguqukayo we-HER2, kuyilapho ama-TKI omugqa wokuqala ekhombisa isithembiso, ukuphathwa kwesifo sangemuva kokuqhubekela phambili kuhlala kuyindawo yophenyo olusebenzayo. Ama-antibody-drug conjugates ayaqhubeka nokudlala indima ebalulekile lapha, enikeza indlela yokusebenza ehlukile kune-kinase inhibition.

Ukufinyeleleka kanye Nokulingana

Izindleko eziphakeme zama-ejenti anoveli kanye nokuhlolwa okuyinkimbinkimbi kokuxilonga kubangela isithiyo ekufinyeleleni kwendawo yonke. Izinyathelo zokunciphisa izindleko ngokusebenzisa ama-biosimilars kanye nokufakiwe okujwayelekile kubalulekile. Ukwengeza, amathuluzi ezempilo e-telemedicine nawedijithali ayasetshenziswa ukuletha ukubonisana kochwepheshe ezindaweni ezikude, ukuvala igebe kwikhwalithi yokunakekelwa.

Imizamo yokuqeda ukungalingani ihlanganisa nezinhlelo zokuhlola umphakathi kanye nemikhankaso yokufundisa ukuze kutholakale umdlavuza wamaphaphu kusenesikhathi, ezigabeni ezilapheka kakhulu. Ukutholwa kusenesikhathi kuseyisu elisebenza kahle kakhulu lokunciphisa amanani okufa emhlabeni jikelele.

Imibuzo Evame Ukubuzwa Mayelana Nokwelashwa Komdlavuza Wamaphaphu

Iziguli zivame ukuba nemibuzo ethile mayelana nama-nuances okuxilongwa kwazo kanye nezinketho zokwelashwa. Ukubhekana nale mibuzo evamile kusiza ekunciphiseni isimo sezokwelapha esiyinkimbinkimbi sango-2026.

Ingabe ukuhlinzwa kuseyinketho yomdlavuza wamaphaphu wesigaba sesi-III?

Ukuhlinzwa kwesifo sesigaba sesi-III kuyakhetha kakhulu futhi ngokuvamile kugcinelwe amaqeqebana athile athile (isb., T3N1 noma i-T4N0 ekhethiwe) ngemva kokwelashwa kwe-neoadjuvant ngempumelelo. Iziguli eziningi zesigaba III ziphathwa nge-chemoradiation eqondile elandelwa yi-consolidation immunotherapy. Isiteji esihlaselayo siyisibopho ukuze kugwenywe isifo sama-nodal esingenakunqandeka.

Kuthatha isikhathi esingakanani ukuhlola i-biomarker?

Izikhathi zokushintsha ziyahlukahluka ngelebhorethri kodwa ngokuvamile zisukela ezinsukwini eziyi-7 kuye kweziyi-14 kumaphaneli e-NGS aphelele. Ukuhlola okusheshayo okusekelwe ku-plasma kunganikeza imiphumela yokuqala ngokushesha. Odokotela bayelulekwa ukuthi balinde imiphumela egcwele ngaphambi kokuzibophezela ohlelweni lokwelapha lwesikhathi eside, ngaphandle kwasezindaweni eziphuthumayo.

Iyini imiphumela emibi yemithi emisha eqondiwe?

Nakuba ngokuvamile ibekezelelwa kangcono kune-chemotherapy, i-TKIs ingabangela izehlakalo ezithile ezingezinhle njengokuqubuka, isifo sohudo, noma isifo samaphaphu esiphakathi. Ukuqapha njalo nokuphatha okusebenzayo kubalulekile. Iphrofayili yokuphepha yama-ejenti amasha njenge-zonugritinib ikhombisa izehlakalo eziphansi zobuthi obunzima, futhi izehlakalo eziningi ziyalawuleka.

Isiphetho: Inkathi Ye-Precision Oncology

Unyaka ka-2026 umaka inkathi eqondile ukwelashwa komdlavuza wamaphaphu okuyinhloko, ebonakala ngokwenza kube ngokwakho nokunemba okungakaze kubonwe ngaphambili. Kusukela ekwamukelweni komhlaba wonke kwesiteji se-AJCC 9th Edition kuya ekuhlanganisweni kwama-ejenti ahlosiwe anoveli ezinguqukweni ezingavamile ezifana ne-HER2, inkundla ikhule kakhulu. Ukugcizelelwa kokuhlolwa okuphelele kwe-biomarker kuqinisekisa ukuthi sonke isiguli sithola ukwelashwa okuhambisana ne-tumor biology yaso ehlukile.

Njengoba ucwaningo luqhubeka nokudalula ubunkimbinkimbi bomdlavuza wamaphaphu, igebe phakathi kokuxilongwa nokwelashwa okuphumelelayo liyancipha. Izindlela ezintsha zokulethwa kwezidakamizwa, amasu emisebe, kanye nezithombe zokuxilonga zithuthukisa ikhithi yamathuluzi yodokotela. Nakuba izinselele eziphathelene nokungazweli nokufinyeleleka zisekhona, umkhondo ucacile: ikusasa lapho umdlavuza wamaphaphu ulawulwa kakhulu njengesimo esingelapheki, esilawulekayo esikhundleni sokuxilongwa okubulalayo.

Iziguli nabahlinzeki ngokufanayo kufanele bahlale benolwazi mayelana nalokhu kuthuthuka okusheshayo. Ukunamathela eziqondisweni ezibuyekeziwe, ukubamba iqhaza ezivivinyweni zokwelashwa, nokuzibophezela ekunakekelweni kwemikhakha eminingi kuyizinsika zempumelelo kulo mkhakha wezwe othuthukayo. Uhambo oluya ekuqedeni umdlavuza wamaphaphu njengembangela ehamba phambili yokufa luyaqhubeka, luqhutshwa isayensi, ububele, kanye nokusungula izinto ezintsha ezingapheli.